Rituximab for treatment of ocular inflammatory disease: A series of four cases

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Rituximab may be effective in the treatment of ocular inflammatory disease. Dosing is less frequent than many medications currently available. Four cases are reported, each of which appeared to have responded well to treatment with rituximab, although patient 2 was able to remain on a low dose of prednisone for only 2 months. The ongoing pilot study will hopefully provide additional insight into the benefit of rituximab for treatment of scleritis and idiopathic orbital inflammatory disease.

Original languageEnglish (US)
Pages (from-to)546-548
Number of pages3
JournalBritish Journal of Ophthalmology
Volume93
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Eye Diseases
Orbital Diseases
Scleritis
Prednisone
Therapeutics
Rituximab

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

@article{c48086c37bd04fa4830a61bd2ece32e0,
title = "Rituximab for treatment of ocular inflammatory disease: A series of four cases",
abstract = "Rituximab may be effective in the treatment of ocular inflammatory disease. Dosing is less frequent than many medications currently available. Four cases are reported, each of which appeared to have responded well to treatment with rituximab, although patient 2 was able to remain on a low dose of prednisone for only 2 months. The ongoing pilot study will hopefully provide additional insight into the benefit of rituximab for treatment of scleritis and idiopathic orbital inflammatory disease.",
author = "Kurz, {P. A.} and Eric Suhler and Dongseok Choi and Rosenbaum, {James (Jim)}",
year = "2009",
month = "4",
doi = "10.1136/bjo.2007.133173",
language = "English (US)",
volume = "93",
pages = "546--548",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Rituximab for treatment of ocular inflammatory disease

T2 - A series of four cases

AU - Kurz, P. A.

AU - Suhler, Eric

AU - Choi, Dongseok

AU - Rosenbaum, James (Jim)

PY - 2009/4

Y1 - 2009/4

N2 - Rituximab may be effective in the treatment of ocular inflammatory disease. Dosing is less frequent than many medications currently available. Four cases are reported, each of which appeared to have responded well to treatment with rituximab, although patient 2 was able to remain on a low dose of prednisone for only 2 months. The ongoing pilot study will hopefully provide additional insight into the benefit of rituximab for treatment of scleritis and idiopathic orbital inflammatory disease.

AB - Rituximab may be effective in the treatment of ocular inflammatory disease. Dosing is less frequent than many medications currently available. Four cases are reported, each of which appeared to have responded well to treatment with rituximab, although patient 2 was able to remain on a low dose of prednisone for only 2 months. The ongoing pilot study will hopefully provide additional insight into the benefit of rituximab for treatment of scleritis and idiopathic orbital inflammatory disease.

UR - http://www.scopus.com/inward/record.url?scp=64749117073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64749117073&partnerID=8YFLogxK

U2 - 10.1136/bjo.2007.133173

DO - 10.1136/bjo.2007.133173

M3 - Article

C2 - 19321476

AN - SCOPUS:64749117073

VL - 93

SP - 546

EP - 548

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 4

ER -